Clinical Trial Update: New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a new retinoid agent in combination with arsenic trioxide for untreated acute promyelocytic leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Promyelocytic Leukemia

Drugs mentioned

• Arsenic Trioxide (arsenic trioxide)
• New Retinoid Agent

Snippet

Sponsor: University of Southern California | Conditions: Acute Promyelocytic Leukemia | Phase 2 | Status: WITHDRAWN